Skip to main content
Press release

Pharming announces completion of acquisition of all North American commercialisation rights for RUCONEST® from Valeant

Pharming announces today that it has completed a definitive agreement to acquire all North American commercialisation rights for its own product, RUCONEST® (recombinant human C1 esterase inhibitor), including all rights in the US, Mexico and Canada, from certain subsidiaries of Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX).

Read more

Filter

Cookies: This website uses cookies Check the cookies page for more information Accept Decline